EWA
CTNM

EverSource Wealth Advisors’s Contineum Therapeutics CTNM Stock Holding History

EverSource Wealth Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48
Closed -$564 – 4480
2025
Q3 		$564 Buy
48
+37
+336% +$298 ﹤0.01% 3920
2025
Q2 		$44 Buy
11
+3
+38% +$13 ﹤0.01% 4202
2025
Q1 		$56 Buy
8
+5
+167% +$45 ﹤0.01% 3890
2024
Q4 		$44 Buy
+3
New +$48 ﹤0.01% 3653

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EverSource Wealth Advisors's CTNM Position: Q4 2025 in Review

EverSource Wealth Advisors sold out of Contineum Therapeutics (CTNM) in Q4 2025, closing a stake of 48 shares — an estimated $564 sold.

EverSource Wealth Advisors first reported a position in CTNM in Q4 2024 and held it in 4 quarters. The position peaked at $564 in Q3 2025. 80 funds tracked by Wall St. Rank hold CTNM as of Q4 2025.

  • EverSource Wealth Advisors reported no remaining Contineum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 48 Contineum Therapeutics shares in Q4 2025, an estimated $564.
  • EverSource Wealth Advisors first reported a position in Contineum Therapeutics in Q4 2024 and held it in 4 quarters.
  • EverSource Wealth Advisors's Contineum Therapeutics position peaked at $564 in Q3 2025.
  • 80 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q4 2025.

Based on EverSource Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.